Wade Iams, MD
Hematology & Oncology · Nashville, TNNPI 1134485410
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.9%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 33 manufacturers reported payments, led by Amgen at 28.0% of the total. 2025 is the largest year on record at $316,497, more than ten times the $2,726 reported in 2019. Among hematology & oncology clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 475 payments — averaging $1265.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$168K
- Novocure Inc.$102K
- Jazz Pharmaceuticals Inc.$88K
- EMD Serono, Inc.$37K
- AbbVie$30K
- Sanofi$27K
- plus $149K from 27 others
Across 545 payments — averaging $15,314 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$3M
- Takeda Pharmaceuticals U.S.A., Inc.$1.4M
- EMD Serono, Inc.$885K
- AstraZeneca$788K
- E.r. Squibb & Sons, L.L.C.$461K
- Eli Lilly$446K
- plus $1.4M from 8 others
What the payments were for
- Consulting fees$212,13135%
- Speaking & faculty fees$329,81455%
- Travel & lodging$46,5358%
- Food & beverage$12,1312%
- Education$5270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 130 | $168,138 |
| Novocure Inc. | 80 | $101,696 |
| Jazz Pharmaceuticals Inc. | 39 | $88,457 |
| EMD Serono, Inc. | 23 | $36,759 |
| AbbVie | 24 | $29,821 |
| Sanofi | 18 | $26,809 |
| AstraZeneca | 15 | $23,932 |
| Genentech USA, Inc. | 21 | $23,259 |
| Johnson & Johnson | 19 | $18,966 |
| Daiichi Sankyo Inc. | 14 | $14,469 |
| E.r. Squibb & Sons, L.L.C. | 17 | $12,655 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $8,683 |
| Partner Therapeutics, Inc. | 11 | $7,180 |
| Regeneron Healthcare Solutions, Inc. | 13 | $5,534 |
| Janssen Scientific Affairs, LLC | 6 | $5,479 |
| Lilly USA, LLC | 2 | $5,200 |
| Catalyst Pharmaceuticals, Inc. | 5 | $4,087 |
| Merck | 5 | $4,038 |
| Gilead(2 entities) | 7 | $3,838 |
| Regeneron | 3 | $2,666 |
| Nuvation Bio Inc. | 1 | $2,520 |
| Boehringer Ingelheim | 2 | $1,755 |
| Bayer | 1 | $1,607 |
| Pfizer | 1 | $1,590 |
| Galvanize Therapeutics, Inc | 1 | $1,200 |
| Genentech, Inc. | 4 | $410 |
| Stemline Therapeutics Inc. | 1 | $119 |
| Novartis | 4 | $99 |
| Astellas Pharma US Inc | 2 | $56 |
| Dendreon Pharmaceuticals LLC | 1 | $44 |
| Legend Biotech USA Inc. | 1 | $37 |
| GSK | 1 | $20 |
| Spectrum Pharmaceuticals Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IMDELLTRA (AMG 757)$99,737
- ZEPZELCA$88,017
- OPTUNE LUA (NOVOTTF-200T)$75,966
- EMRELIS$23,217
- RYBREVANT$22,514
- Tepmetko$16,034
- LIBTAYO$12,197
- TAGRISSO$9,435
- ALUNBRIG$8,683
- IMFINZI$8,418
- TECENTRIQ$8,018
- Bizengri$6,802
- RETEVMO$5,200
- LUMAKRAS$4,868
- FIRDAPSE$3,950
- Enhertu$2,996
- IBTROZI$2,520
- Alecensa$2,421
- ROZLYTREK$2,421
- GAVRETO$2,421
How this compares
$601,138 in reported general payments places this provider in the 95th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 69 | $1,062,338 |
| AlunbrigBrigatinib | 11 | $211,635 |
| Gefitinib | 16 | $54,297 |
| EliquisApixaban | 73 | $52,051 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $6,513 |
| Advair DiskusFluticasone Propion/Salmeterol | 11 | $2,741 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,730 |
| Dronabinol | 11 | $1,293 |
| Oxycodone Hcl | 58 | $1,206 |
| Morphine Sulfate ErMorphine Sulfate | 12 | $1,130 |
| Gabapentin | 82 | $984 |
| Ondansetron Hcl | 41 | $941 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 12 | $930 |
| Prochlorperazine Maleate | 35 | $730 |
| Ventolin HfaAlbuterol Sulfate | 11 | $626 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $23,932 | $1,062,33869 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Alunbrig | $8,683 | $211,63511 claims |
| PfizerEliquis | $1,590 | $52,05173 claims |
| Lilly USA, LLCOlanzapine | $5,200 | $11720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Nashville
- Jonathan AbbasNashville$1.3M
- Alan TanNashville$1.1M
- Kent ShihNashville$900K
- Brian RiniNashville$601K
- Krish PatelNashville$531K
- Sandeep RajanNashville$465K
- Todd BauerNashville$357K
- Muhamed BaljevicNashville$313K
- Olalekan OluwoleNashville$311K
- Jack ErterNashville$228K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.